Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy Infectious Diseases

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Kim, Tiffany ^a,b   Kandiah, Sheetal ^a,c   Patel, Manish ^a   Rab, Saira ^a   Wong, Jordan ^a   Xue, Wenqiong ^d,e   Easley, Kirk ^e   Anderson, Albert M ^a,c  

^a GRADY HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Acute kidney injury; Piperacillin; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DOSE RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTOR;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PENICILLANIC ACID; PIPERACILLIN; REGRESSION ANALYSIS; RISK FACTORS; VANCOMYCIN;

EID: 84944326575     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1518-9     Document Type: Article

References (28)

1. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237-48.
2. Ansari F, Erntell M, Goossens H, Davey P. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49(10):1496-504.
3. Ingram PR, Seet JM, Budgeon CA, Murray R. Point-prevalence study of inappropriate antibiotic use at a tertiary Australian hospital. Intern Med J. 2012;42(6):719-21.
4. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis Off Publ Infect Dis Soc Am. 1997;24(3):471-85.
5. Polgreen PM, Chen YY, Cavanaugh JE, Ward M, Coffman S, Hornick DB, Diekema DJ, Herwaldt LA. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am. 2007;28(2):212-4.
6. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol JASN. 2005;16(11):3365-70.
7. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983;74(2):243-8.
8. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;37(3):382-9.
9. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68(9):1243-55.
10. Murray KM, Keane WR. Review of drug-induced acute interstitial nephritis. Pharmacotherapy. 1992;12(6):462-7.
11. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007;35(8):1837-43 quiz 1852.
12. Groeger JS, Strosberg MA, Halpern NA, Raphaely RC, Kaye WE, Guntupalli KK, Bertram DL, Greenbaum DM, Clemmer TP, Gallagher TJ, et al. Descriptive analysis of critical care units in the United States. Crit Care Med. 1992;20(6):846-63.
13. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-12.
14. Van Biesen W, Vanholder R, Lameire N. Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol CJASN. 2006;1(6):1314-9.
15. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury N. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
16. Breiman L. Bagging predictors. Mach Learn. 1996;24(2):123-40.
17. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399-424.
18. Hellwig T, Hammerquist, R. Critical Care Congress 2012 Poster 301: Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure. Crit Care Med 39 (supplement 12). In: Houston, Texas; 2012.
19. Min E, Box K, Lane J, Sanchez J, Coimbra R, Doucet J, Potenza B, Wargel L. Critical Care Congress 2012 Poster 714: Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam. Critical Care Medicine volume 79 (supplement 12). In: Houston, Texas; 2012.
20. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670-6.
21. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy. 2014;34(7):653-61.
22. Baldwin DS, Levine BB, McCluskey RT, Gallo GR. Renal failure and interstitial nephritis due to penicillin and methicillin. N Engl J Med. 1968;279(23):1245-52.
23. Gomes DM, Smotherman C, Birch A, Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34(7):662-9.
24. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20(6):O384-9.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. AKI definition. Kidney Int Suppl. 2012;2:19-36.
26. Moh'd H, Kheir F, Kong L, Du P, Farag H, Mohamad A, Zurlo JJ. Incidence and predictors of vancomycin-associated nephrotoxicity. South Med J. 2014;107(6):383-8.
27. Shoker A, Hossain MA, Koru-Sengul T, Raju DL, Cockcroft D. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol. 2006;66(2):89-97.
28. Vincent JL, Ferreira F, Moreno R. Scoring systems for assessing organ dysfunction and survival. Crit Care Clin. 2000;16(2):353-66.